The company
Lyell Immunopharma, Inc.
LYEL · Nasdaq
LYEL stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 26 weeks. It is 36.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 26
- Industry in uptrend
- 18% -14 in 4 wk
- Insider buys, 12 months
- $50.0M
- Insider sales, 12 months
- $1.2M
- Officials’ trades on record
- 0
- Institutions holding
- 84 (+13)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Jarrad Mattieu AguirreChief Medical Officer | sold | 422at $8.63 | 12 Oct 2026filed 13 Oct 2026 |
| David ShookChief Medical Officer | sold | 500at $12.70 | 10 Sep 2026filed 10 Sep 2026 |
| Lynn SeelyPresident and CEO | sold | 9,589at $15.54 | 21 Aug 2026filed 25 Aug 2026 |
| Stephen J. HillChief Operating Officer | sold | 989at $15.54 | 21 Aug 2026filed 25 Aug 2026 |
| Gary K. LeeChief Scientific Officer | sold | 1,457at $15.54 | 21 Aug 2026filed 25 Aug 2026 |
| Lynn SeelyPresident and CEO | sold | 390at $14.34 | 10 Aug 2026filed 11 Aug 2026 |
| Stephen J. HillChief Operating Officer | sold | 89at $14.34 | 10 Aug 2026filed 11 Aug 2026 |
| Gary K. LeeChief Scientific Officer | sold | 131at $14.34 | 10 Aug 2026filed 11 Aug 2026 |
| Veronica Sanchez BulisVP, Corporate Controller | sold | 621at $14.34 | 10 Aug 2026filed 11 Aug 2026 |
| Innovative Cellular Therapeutics Holdings Ltd10% owner | sold | 10at $13.70 | 17 Jul 2026filed 20 Jul 2026 |
| Innovative Cellular Therapeutics Holdings Ltd10% owner | sold | 10at $13.73 | 16 Jul 2026filed 17 Jul 2026 |
| David ShookChief Medical Officer | sold | 1,977at $12.64 | 10 Jun 2026filed 11 Jun 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| ARCH Venture Management, LLCunchanged · filed 14 Aug 2026 | 3,247,162$45.5M | 00.0% |
| GSK plcunchanged · filed 13 Aug 2026 | 1,512,659$21.3M | 00.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 786,774$11.1M | +68,619+9.6% |
| Orland Properties Ltdunchanged · filed 5 Aug 2026 | 754,698$10.6M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 724,342$10.2M | +532,522+277.6% |
| Decheng Capital LLCunchanged · filed 14 Aug 2026 | 692,050$9.7M | 00.0% |
| Almitas Capital LLCadded · filed 17 Aug 2026 | 581,407$8.2M | +3,600+0.6% |
| Foresite Capital Management V, LLCreduced · filed 14 Aug 2026 | 476,386$6.7M | -692−0.1% |
| MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026 | 367,473$5.2M | -91,432−19.9% |
| Opaleye Management Inc.added · filed 14 Aug 2026 | 344,025$4.8M | +264,928+334.9% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.